Follow-Up Plan for Dermatological Conditions
Timing of Follow-Up Visits
- The British Journal of Dermatology recommends that follow-up visits should be scheduled weekly to biweekly until disease control is achieved, then monthly for the next 3 months, followed by every 2 months to three times a year until treatment is stopped 1
- The frequency of follow-up should be adapted to the patient's clinical condition, disease severity and evolution, treatments used, and local health practices 1
- For patients with generalized disease, follow-up should be more frequent initially (weekly to biweekly) until the condition is controlled 1
- After disease control is achieved, monthly visits for 3 months are recommended, then extending to every 2 months to three times a year 1
- The monitoring frequency should be adjusted based on the disease course and treatment response 1
Focus of Next Visit
- Clinical examination should focus on skin disease activity, possible treatment-related side effects and comorbidities, and the degree of skin atrophy, purpura, and skin infections 1
- Laboratory monitoring should include blood pressure monitoring, analysis of white blood cells, liver and kidney tests, glycemic value monitoring, and immune serological analyses 1
- Treatment assessment should include evaluation of medication efficacy, safety, and tolerance 1
- Assessment of patient compliance with prescribed therapy should be considered 2
- Consideration of treatment adjustments based on clinical response should be taken into account 2
Special Considerations
- If the patient is on systemic corticosteroids for more than 3 months, monitor for osteoporosis and consider vitamin D and calcium supplementation 1
- For patients at risk, consider bisphosphonate treatment to prevent osteoporosis 1
- If treatment fails, consider non-compliance, incorrect diagnosis, development of contact allergy to medication, or superimposed conditions 4
- Consider osteodensitometry and ocular examination if indicated according to the treatment regimen and the patient's age and condition 1
Treatment Discontinuation Planning
- The optimal duration of treatment has not been defined but is generally 4-12 months according to disease severity 1
- Discontinuation of treatment should be considered in patients who are free of symptoms for at least 1-6 months under minimal therapy 1
- Prior to cessation of treatment, DIF studies and/or ELISA for BP180 should be performed to assess risk of relapse 1